

OssDsign Q2 - Strong sales but higher costs ahead

Redeye returns with a more in-depth take on the Q2 report. The report was in line with our estimates, and the strong sales growth ignited a significant share price rally. Around the corner, we see increasing costs and CAPEX. We decrease our base and bull cases.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

OssDsign Q2 - Strong sales but higher costs ahead